Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
Trial details
- Registry ID
- NCT04728347
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021NCT04728347 | Arcturus Therapeutics, Inc. | Phase 2 | Terminated | 2021-12-28Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |